See today's BioWorld
To read the full story, subscribe or sign in.

Following the Blueprint for expansion-ISM: FDA says yes to widened label in rare mast-cell disease

May 23, 2023
By Randy Osborne
Blueprint Medicines Corp. scored a broader label from the U.S. FDA for Ayvakit (avapritinib), which became the first approved therapy to treat adults with indolent systemic mastocytosis (ISM).
BioWorld Regulatory Musculoskeletal FDA